Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae
暂无分享,去创建一个
Stacey D. Finley | Colin G. Cess | J. Li | T. Velkov | G. Rao | Rajnikant Sharma | Nusaibah Abdul Rahim | P. Hanafin | P. Bergen
[1] Matthew D. Johnson,et al. Synergy of the Polymyxin-Chloramphenicol Combination against New Delhi Metallo-β-Lactamase-Producing Klebsiella pneumoniae Is Predominately Driven by Chloramphenicol. , 2021, ACS infectious diseases.
[2] Neang S. Ly,et al. Moving From Point‐Based Analysis to Systems‐Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria , 2021, Clinical pharmacology and therapeutics.
[3] J. Li,et al. Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection Model , 2021, Clinical pharmacology and therapeutics.
[4] Amy K. Cain,et al. The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii , 2020, Frontiers in Microbiology.
[5] Matthew D. Johnson,et al. Transcriptomic responses of a New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol. , 2020, International journal of antimicrobial agents.
[6] Brian T. Tsuji,et al. Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae , 2020, Antimicrobial Agents and Chemotherapy.
[7] K. Ko,et al. Effect of colistin-based antibiotic combinations on the eradication of persister cells in Pseudomonas aeruginosa. , 2020, The Journal of antimicrobial chemotherapy.
[8] C. L. Cardoso,et al. Synergistic activity of polymyxin B combined with vancomycin against carbapenem‐resistant and polymyxin‐resistant Acinetobacter baumannii: first in vitro study , 2019, Journal of medical microbiology.
[9] K. Holt,et al. Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria. , 2018, Current opinion in microbiology.
[10] M. Ouellette,et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.
[11] G. Rao,et al. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae , 2017, Antimicrobial Agents and Chemotherapy.
[12] C. Landersdorfer,et al. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes , 2017, Antimicrobial Agents and Chemotherapy.
[13] Salman Motlekar,et al. Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence , 2017, Critical care research and practice.
[14] I. Androulakis,et al. Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels , 2017, Front. Pharmacol..
[15] Neang S. Ly,et al. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes. , 2017, International journal of antimicrobial agents.
[16] R. Hancock,et al. Polymyxin: Alternative Mechanisms of Action and Resistance. , 2016, Cold Spring Harbor perspectives in medicine.
[17] Neang S. Ly,et al. Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii. , 2016, International journal of antimicrobial agents.
[18] M. Gustafsson,et al. Facing the challenges of multiscale modelling of bacterial and fungal pathogen–host interactions , 2016, Briefings in functional genomics.
[19] Matthew D. Johnson,et al. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol. , 2015, The Journal of antimicrobial chemotherapy.
[20] Brian T. Tsuji,et al. Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use , 2015, Pharmacotherapy.
[21] Kidakan Saithanu,et al. CUTOFF THRESHOLD OF VARIABLE IMPORTANCE IN PROJECTION FOR VARIABLE SELECTION , 2014 .
[22] M. Falagas,et al. Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections , 2014, Emerging infectious diseases.
[23] M. Antonelli,et al. Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria , 2013, Antimicrobial Agents and Chemotherapy.
[24] N. Zenkin,et al. Molecular mechanism of bacterial persistence by HipA. , 2013, Molecular cell.
[25] M. Falagas,et al. Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence , 2013, Antimicrobial Agents and Chemotherapy.
[26] R. Nation,et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. , 2013, Future microbiology.
[27] C. Landersdorfer,et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] D. Paterson,et al. Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens , 2012, Antimicrobial Agents and Chemotherapy.
[29] Alimuddin Zumla. Mandell, Douglas, and Bennett's principles and practice of infectious diseases , 2010, The Lancet Infectious Diseases.
[30] C. Herrera,et al. Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides , 2010, Molecular microbiology.
[31] D. Calfee,et al. Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection , 2009, Journal of Clinical Microbiology.
[32] J. Abranches,et al. The Molecular Alarmone (p)ppGpp Mediates Stress Responses, Vancomycin Tolerance, and Virulence in Enterococcus faecalis , 2009, Journal of bacteriology.
[33] J. Li,et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] Joel T. Smith,et al. The global, ppGpp‐mediated stringent response to amino acid starvation in Escherichia coli , 2008, Molecular microbiology.
[35] J. Rahal. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] E. Groisman,et al. The PmrA-Regulated pmrC Gene Mediates Phosphoethanolamine Modification of Lipid A and Polymyxin Resistance in Salmonella enterica , 2004, Journal of bacteriology.
[37] Alan Forrest,et al. Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.
[38] S. Wold,et al. PLS-regression: a basic tool of chemometrics , 2001 .
[39] T. Johns,et al. Laboratory guidelines for monitoring of antimicrobial drugs , 1998 .
[40] P. Ambrose. Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate , 1984, Clinical pharmacokinetics.
[41] R. Slaughter,et al. Chloramphenicol Pharmacokinetics in Hospitalized Patients , 1979, Antimicrobial Agents and Chemotherapy.
[42] Y. Sokawa,et al. Relaxation effect of chloramphenicol on the stringent control in Escherichia coli. , 1978, Journal of biochemistry.
[43] J. Gallant,et al. On the turnover of ppGpp in Escherichia coli. , 1972, The Journal of biological chemistry.
[44] R. M. Smith,et al. Chloromycetin, a New Antibiotic From a Soil Actinomycete. , 1947, Science.
[45] O. Zusman,et al. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis , 2017, The Journal of antimicrobial chemotherapy.
[46] Brad Spellberg,et al. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] J. Mouton. Combination therapy as a tool to prevent emergence of bacterial resistance , 1999, Infection.